Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study for Patients with Cardiovascular and Metabolic Diseases
Shots:
- The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC- 40-80mg) vs PBO in 105 patients with hypertriglyceridemia- T2D- and NAFLD for 6mos.
- The P-II study resulted in meeting its primary & multiple secondary endpoints with a reduction in fasting triglycerides- ANGPTL3- apoC-III- VLDL-C- non-HDL cholesterol- no reduction in liver fat and is well tolerated
- AKCEA-ANGPTL3-LRx is an investigational antisense therapy- designed to reduce the production of ANGPTL3. Additionally- in 2019- Akcea signed a WW exclusive license agreement with Pfizer for the therapy under which Pfizer is responsible for all development and regulatory activities and costs beyond those associated with P-II study
Click here to read full press release/ article | Ref: Akcea | Image: Akcea
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com